Estie Mermelstein, MSN, FNP-BC

Researchers sought to develop a model to predict the 2-year risk of developing psoriatic arthritis in patients with psoriasis.

Researchers evaluated patients with documented care for long COVID to determine factors associated with its occurrence.

Researchers evaluated the accuracy of machine learning models to predict COVID-19 severity on the basis of patient characteristics and laboratory data.

Researchers assessed the safety and efficacy of subcutaneous casirivimab/imdevimab for the prevention of COVID-19 infection.

Researchers assessed the efficacy of corticosteroids for the treatment of COVID-19 infection.

COVID-19 outcomes in patients with dermatomyositis are compared with those of the general population.

Researchers compared immune responses following COVID-19 vaccination with the mRNA-1273 vs the BNT162b2 vaccines among patients with rheumatic and musculoskeletal diseases and solid organ transplant recipients.

Investigators compared treatment with interleukin-6 inhibitors with standard of care among patients hospitalized with COVID-19 infection.

The effectiveness of risankizumab (RZB) in treating fingernail psoriasis in patients with psoriatic arthritis is reported.

A study examines the relationship between serum chemerin and disease activity in women with rheumatoid arthritis (RA).

Incidence of, and risk factors for, lumbar lesions in RA are examined in a longitudinal study.

Does local joint swelling recur in the same joints in patients with rheumatoid arthritis?

The efficacy and safety of filgotinib in methotrexate-naïve patients with RA with poor prognostic factors is examined.

A prophylaxis regime to prevent pneumocystis pneumonia in patients with RA treated with b/tsDMARDs is reported.

The effect of psoriasis treatment with biologic agents and incidence of psoriatic arthritis is examined.

Event and incidence rates of herpes zoster in patients with RA treated with biologic, tsDMARDs are compared.

Investigators conducted a systemic review to assess the effects of various medications on seroconversion rates following SARS-CoV-2 vaccination in patients with immune mediated inflammatory disease.

Investigators conducted a multiplatform trial to compare the effects of therapeutic-dose heparin with standard care thromboprophylaxis for the treatment of patients hospitalized with moderate COVID-19.

Investigators compared adverse effects of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines reported in the COVID Symptom Study App with those reported during phase 3 trials.

Randomized, controlled trials in pediatric inflammatory rheumatic diseases (PiRDs) of patients who underwent bDMARDs and JAK inhibitors are reviewed.

Investigators assessed the immune response to Clostridioides difficile in immunocompromised patients.

Investigators assessed the role of cell-mediated immunity in the development of cytomegalovirus infection in patients with systemic lupus erythematosus undergoing treatment with immunosuppressants.

Investigators assessed response to vaccination with the Moderna or Pfizer-BioNTech COVID-19 vaccines in pregnant and nonpregnant lactating women.

Investigators vaccinated exclusively or partially breastfeeding women and examined their breast milk samples to determine levels of antibodies against SARS-CoV-2.

The effects of 1-year of tofacitinib therapy on bone metabolism in patients with rheumatoid arthritis were examined.

The investigators reported efficacy results from the MAXIMISE trial, the first randomized controlled trial evaluating the efficacy of a biologic agent in the treatment of axial manifestations in PsA.

Study authors conducted a systematic review and meta-analysis to assess the efficacy of Janus kinase-inhibitors and Type I interferons as potential antiviral candidates for the treatment of COVID-19.

Investigators determined whether ABO and Rh blood groups were associated with risk for SARS-CoV-2 infection and severe COVID-19 illness.

The mucocutaneous features seen in hospitalized children with MIS-C and how these findings are associated with the onset of systemic symptoms are characterized.